Targeting aberrant TGF-beta signaling in pre-clinical models of cancer

Area of Science:

• Cellular Biology
• Molecular Signaling
• Pathology

Background:

• The Transforming Growth Factor-beta (TGF-beta) signaling pathway governs critical cellular processes like proliferation, apoptosis, and immune responses.
• Dysregulation of TGF-beta signaling is linked to various pathologies, including fibrosis, asthma, cardiovascular disease, and cancer.

Purpose of the Study:

• To review current therapeutic strategies and inhibitors targeting the TGF-beta signaling pathway.
• To discuss the potential of these inhibitors as anti-cancer therapeutics, particularly in pre-clinical models.
• To consider the complexities and potential consequences of targeting TGF-beta in disease treatment.

Main Methods:

• Review of existing literature on TGF-beta pathway inhibitors.
• Discussion of various inhibitor classes: knock-down strategies, neutralizing antibodies, ligand traps, and small molecule kinase inhibitors.
• Analysis of pre-clinical data for anti-cancer therapeutic strategies.

Main Results:

• Several classes of TGF-beta signaling inhibitors are under development.
• TGF-beta's dual role in cancer, acting as a tumor suppressor early on and a promoter of invasion later, complicates therapeutic targeting.
• Pre-clinical studies show promise for some inhibitors in anti-cancer applications.

Conclusions:

• Targeting the TGF-beta pathway offers potential therapeutic avenues for various diseases, especially cancer.
• The efficacy and timing of TGF-beta inhibition are critical considerations due to its complex roles in disease progression.
• Further research is needed to fully understand and mitigate potential adverse effects of TGF-beta pathway inhibition.